{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:17:50Z","timestamp":1773127070522,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lungcan.2023.107389","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:33:06Z","timestamp":1696537986000},"page":"107389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The predictive value of 18F-FDG PET\/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6380-4655","authenticated-orcid":false,"given":"Xiaoqin","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107389_b0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107389_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"Journal of the National Cancer Center"},{"key":"10.1016\/j.lungcan.2023.107389_b0015","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"a systematic review and meta-analysis of individual participant data","volume":"383","author":"Preoperative chemotherapy for non-small-cell lung cancer","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107389_b0020","doi-asserted-by":"crossref","unstructured":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Bmj. 1995;311:899-909.","DOI":"10.1136\/bmj.311.7010.899"},{"issue":"22","key":"10.1016\/j.lungcan.2023.107389_b0025","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107389_b0030","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107389_b0035","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","article-title":"Current status of immune checkpoint inhibition in early-stage NSCLC","volume":"30","author":"Vansteenkiste","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107389_b0040","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107389_b0050","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.lungcan.2023.107389_b0055","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2023.107389_b0060","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2023.107389_b0065","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107389_b0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00339-4","article-title":"First-line treatment of non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors","volume":"33","author":"Bylicki","year":"2019","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107389_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0477-9","article-title":"Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0080","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","article-title":"The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer","volume":"47","author":"Tao","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107389_b0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1996000","article-title":"Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer","volume":"10","author":"Zhao","year":"2021","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.lungcan.2023.107389_b0095","first-page":"9","article-title":"Cancer and inflammation","author":"Munn","year":"2017","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0100","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2023.107389_b0105","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00432-020-03150-9","article-title":"The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors","volume":"146","author":"Castello","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107389_b0110","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107389_b0115","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4143\/crt.2021.1007","article-title":"The role of neutrophil-to-lymphocyte ratio in predicting pathological response for resectable non-small cell lung cancer treated with neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors","volume":"54","author":"Sun","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107389_b0120","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3390\/cancers12082234","article-title":"Association of the metabolic score using baseline FDG-PET\/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab","volume":"12","author":"Seban","year":"2020","journal-title":"Cancers (basel)"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0125","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107389_b0130","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107389_b0135","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtho.2019.08.480","article-title":"OA13.05 NADIM study: updated clinical research and outcomes","volume":"14","author":"Provencio","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107389_b0140","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jnci\/djz094","article-title":"Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis","volume":"111","author":"Conforti","year":"2019","journal-title":"J. Natl Cancer Inst."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107389_b0145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.107389_b0150","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.clon.2022.03.010","article-title":"Gender differences and their effects on survival outcomes in lung cancer patients treated with PD-1\/PD-L1 checkpoint inhibitors: a systematic review and meta-analysis","volume":"34","author":"Madala","year":"2022","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.lungcan.2023.107389_b0155","first-page":"1","article-title":"Relationship between patients' baseline characteristics and survival benefits in immunotherapy-treated non-small-cell lung cancer: a systematic review and meta-analysis","volume":"2022","author":"Hu","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.lungcan.2023.107389_b0160","article-title":"Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2023.107389_b0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2020.05.021","article-title":"Clinical and molecular correlates of tumor mutation burden in non-small cell lung cancer","volume":"146","author":"Sharpnack","year":"2020","journal-title":"Lung Cancer"},{"issue":"7463","key":"10.1016\/j.lungcan.2023.107389_b0170","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"6230","key":"10.1016\/j.lungcan.2023.107389_b0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2023.107389_b0180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: from biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107389_b0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2023.107389_b0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107389_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000406","article-title":"Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature","volume":"3","author":"Norum","year":"2018","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107389_b0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2016.11.013","article-title":"Tumor B7\u2013H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis","volume":"103","author":"Inamura","year":"2017","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107389_b0205","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.21037\/tlcr-22-617","article-title":"International expert consensus on immunotherapy for early-stage non-small cell lung cancer","volume":"11","author":"Liang","year":"2022","journal-title":"Transl Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0210","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581530","article-title":"Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.lungcan.2023.107389_b0215","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2147\/CMAR.S155542","article-title":"Clinical usefulness of (18)F-FDG PET\/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis","volume":"10","author":"Yu","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107389_b0220","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-007-0459-5","article-title":"[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy","volume":"34","author":"Berriolo-Riedinger","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107389_b0225","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s00259-016-3425-2","article-title":"Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery","volume":"43","author":"Lopci","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107389_b0230","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cllc.2018.04.008","article-title":"Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer","volume":"19","author":"Zer","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107389_b0235","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s12094-012-0872-5","article-title":"Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer","volume":"14","author":"Cedr\u00e9s","year":"2012","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.lungcan.2023.107389_b0240","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1038\/srep12493","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis","volume":"5","author":"Gu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2023.107389_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107389_b0250","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3122-y","article-title":"Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer","volume":"17","author":"Derman","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2023.107389_b0255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat. Rev. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:18Z","timestamp":1759237518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":51,"alternative-id":["S0169500223009273"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107389","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The predictive value of 18F-FDG PET\/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107389"}}